Curated News
By: NewsRamp Editorial Staff
September 10, 2026
Quantum BioPharma's Lucid-MS Advances to Phase 2 MS Trial After FDA Clearance
TLDR
- Quantum BioPharma's FDA IND clearance for Lucid-MS positions QNTM ahead in multiple sclerosis with a first-in-class non-immune therapy.
- Lucid-MS, a PAD2 inhibitor, targets demyelination directly and will be tested in a randomized, double-blind, placebo-controlled phase 2 trial.
- Quantum BioPharma's Lucid-MS could improve multiple sclerosis care by addressing demyelination, potentially reversing damage and enhancing patient lives.
- Quantum BioPharma uses a PET tracer with Mass General and Harvard to visualize demyelination, offering a novel way to measure MS progression.
Impact - Why it Matters
This news matters because it signals a potential paradigm shift in multiple sclerosis treatment. Current therapies largely focus on immune suppression, which can leave patients vulnerable to infections and other complications. Lucid-MS, with its novel mechanism targeting demyelination directly, could offer a new way to prevent or even reverse myelin damage—the underlying cause of MS disability. The FDA clearance of the IND application and the planned phase 2 trial represent critical steps toward a potentially disease-modifying therapy. Additionally, the collaboration with Massachusetts General Hospital and Harvard Medical School on the [¹⁸F]3F4AP PET imaging tracer could provide researchers with a powerful tool to visualize and measure demyelination, accelerating drug development not just for MS but for other demyelinating conditions. For investors, Quantum BioPharma's progress, alongside the advancements of peers like Novartis, Merck, TG Therapeutics, and Bristol-Myers Squibb, underscores the vibrant innovation occurring across the biopharma sector, particularly in areas of high unmet need. The company's royalty stream from UNBUZZD™ also adds a diversified revenue angle, making QNTM a stock to watch for those interested in cutting-edge neuroscience and metabolic therapies.
Summary
Quantum BioPharma Ltd. (NASDAQ: QNTM) is making significant strides in multiple sclerosis research, with its lead candidate Lucid-MS advancing toward a randomized, double-blind, placebo-controlled phase 2 trial. This progress follows U.S. Food and Drug Administration clearance of its Investigational New Drug application. Lucid-MS is a patented, first-in-class, non-covalent inhibitor of peptidyl arginine deiminase 2 (PAD2) that is designed to target demyelination directly rather than suppress the immune system. The company also highlighted its research collaboration with Massachusetts General Hospital and Harvard Medical School involving the [¹⁸F]3F4AP PET imaging tracer, which is being evaluated as a method to visualize and measure demyelination.
The editorial places Quantum BioPharma alongside other major pharmaceutical companies advancing therapies in areas of unmet medical need. Novartis AG (NYSE: NVS) received FDA approval for Pluvicto® in combination with an androgen receptor pathway inhibitor for certain patients with metastatic hormone-sensitive prostate cancer. Merck & Co. Inc. (NYSE: MRK) had its supplemental Biologics License Application for ENFLONSIA™ accepted by the FDA to expand its indication for certain children at increased risk for severe respiratory syncytial virus disease. TG Therapeutics Inc. (NASDAQ: TGTX) initiated a phase 2 trial of BRIUMVI® in adults with treatment-resistant schizophrenia. Bristol-Myers Squibb Company (NYSE: BMY) reported positive phase 2 results from the registrational QUINTESSENTIAL trial evaluating arlocabtagene autoleucel in heavily pretreated relapsed and refractory multiple myeloma. To view the full press release, visit https://ibn.fm/lCey9.
Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of its lead compound, Lucid-MS. Quantum invented UNBUZZD™ and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake as of March 31, 2026, and royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity. The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma's Lucid-MS Advances to Phase 2 MS Trial After FDA Clearance
